Evidence map›Paper›PMID 21216000›Full record

Trial reportLancet (London, England)2011

Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda.

Maria J Wawer, Aaron A R Tobian, Godfrey Kigozi, Xiangrong Kong, Patti E Gravitt, David Serwadda, Fred Nalugoda, Frederick Makumbi, Victor Ssempiija, Nelson Sewankambo and 7 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Lancet (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 104 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 8 pooled it
28.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00124878 phase3unknown statusnot on this map

Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community

TypeinterventionalSponsorWawer, Maria J., M.D.Ran2003 to 2009Enrolled5,200ConditionsHIV Infections, Sexually Transmitted Diseases, Papillomavirus Infections, Genital HerpesArmsMale circumcision
NCT00425984 phase3completednot on this map

Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2002 to 2006Enrolled5,000ConditionsHIV Infections, Herpesvirus 2, Human, Syphilis, Genital Diseases, MaleArmsAdult male circumcision
3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 8 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. HIV Transmission and Immunology of the Male Reproductive Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Maria J WawerDepartment of Population, Family, and Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21287, USA.
Aaron A R Tobian
Godfrey Kigozi
Xiangrong Kong
Patti E Gravitt
David Serwadda
Fred Nalugoda
Frederick Makumbi
Victor Ssempiija
Nelson Sewankambo
Stephen Watya
Kevin P Eaton
Amy E Oliver
Michael Z Chen
Steven J Reynolds
Thomas C Quinn
Ronald H Gray
Johns Hopkins University · USMakerere University · UGRakai Health Sciences Program · UGNational Institutes of Health · USJohns Hopkins Medicine · US

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
TUBERCULOSIS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW000010 · FIC · JOHNS HOPKINS UNIVERSITY · PI BEYRER, CHRISTOPHER C. · 1988 to 2012
$19.8M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
Male Circumcision Trial for HIV Prevention, Rakai-UgandaU01AI051171 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2002 to 2006
$8.9M
International Training/Research in Population and Health, UgandaD43TW001508 · FIC · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2000 to 2010
$2.1M
SPECIAL POSTDOCTORAL RESEARCH PROGRAM IN AIDST22TW000015 · FIC · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SCOTT, GWENDOLYN B. · 1988 to 1999
–
FIC NIH HHS 2D43TW000010-19-AITRPFIC NIH HHS 5D43TW001508FIC NIH HHS D43 TW001508FIC NIH HHS T22 TW000015Intramural NIH HHS ZIA AI000361NIAID NIH HHS 3U01-AI075115-03S1NIAID NIH HHS U01 AI051171NIAID NIH HHS U01 AI068613NIAID NIH HHS U1AI51171PHS HHS U01-A1-068613
6 · The paper itself

Abstract

backgroundRandomised trials show that male circumcision reduces the prevalence and incidence of high-risk human papillomavirus (HPV) infection in men. We assessed the efficacy of male circumcision to reduce prevalence and incidence of high-risk HPV in female partners of circumcised men.

methodsIn two parallel but independent randomised controlled trials of male circumcision, we enrolled HIV-negative men and their female partners between 2003 and 2006, in Rakai, Uganda. With a computer-generated random number sequence in blocks of 20, men were assigned to undergo circumcision immediately (intervention) or after 24 months (control). HIV-uninfected female partners (648 of men from the intervention group, and 597 of men in the control group) were simultaneously enrolled and provided interview information and self-collected vaginal swabs at baseline, 12 months, and 24 months. Vaginal swabs were tested for high-risk HPV by Roche HPV Linear Array. Female HPV infection was a secondary endpoint of the trials, assessed as the prevalence of high-risk HPV infection 24 months after intervention and the incidence of new infections during the trial. Analysis was by intention-to-treat. An as-treated analysis was also done to account for study-group crossovers. The trials were registered, numbers NCT00425984 and NCT00124878.

findingsDuring the trial, 18 men in the control group underwent circumcision elsewhere, and 31 in the intervention group did not undergo circumcision. At 24-month follow-up, data were available for 544 women in the intervention group and 488 in the control group; 151 (27·8%) women in the intervention group and 189 (38·7%) in the control group had high-risk HPV infection (prevalence risk ratio=0·72, 95% CI 0·60-0·85, p=0·001). During the trial, incidence of high-risk HPV infection in women was lower in the intervention group than in the control group (20·7 infections vs 26·9 infections per 100 person-years; incidence rate ratio=0·77, 0·63-0·93, p=0·008).

interpretationOur findings indicate that male circumcision should now be accepted as an efficacious intervention for reducing the prevalence and incidence of HPV infections in female partners. However, protection is only partial; the promotion of safe sex practices is also important.

fundingThe Bill & Melinda Gates Foundation, National Institutes of Health, and Fogarty International Center.

Indexed as

Circumcision, MaleAdolescentAdultFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedPapillomavirus InfectionsPrevalenceYoung Adult

Identifiers

PMID21216000
PMCPMC3119044
OpenAlexW2124108668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.